<DOC>
	<DOCNO>NCT01259531</DOCNO>
	<brief_summary>This clinical study design evaluate efficacy safety silodosin 12 week treatment patient severe urinary disorder associate benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Study α1A Adrenoceptor Selective Antagonist Silodosin Treat Severe Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<criteria>Is least 50 year old Has urinary disturbance associate severe BPH total IPSS score 20 high Has QoL score 3 high Has urine volume 120mL great Qmax 15mL/sec Has PRV 100mL Voluntarily decides participate trial sign inform consent form Has administer silodosin Has administer α1Aadrenoceptor blocker within one month Has prescribe antiandrogens except 5αreductase inhibitor within year Has phytotherapy within 3 month Has prostatectomy Has intrapelvic radiation therapy Has transurethral microwave hyperthermia transurethral needle ablation Is suspect implication likely affect urine pass neurogenic bladder , bladder calculus active urinary tract infection ( UTI ) . Is conduct selfcatherterization Has renal impairment serum creatinine 2.0mg/dL great Has severe hepatic disorder ( hepatic insufficiency , cirrhosis , jaundice , hepatoma ) total bilirubin 2.5mg/dl high AST/ALT 2.5 time high normal ( upper ) level Has suffer severe arrhythmia , cardiac failure , cardiac infarction , unstable angina , cerebral infarction within 6 month Has experience allergy α1 receptor blocker Has orthostatic hypotension around time Screening Visit Has participate clinical trial within 8 week prior Screening Visit Has Prostate specific antigen ( PSA ) high 10ng/mL diagnosed tumor identify biopsy even though PSA low 10ng/mL ( Patient administer 5αreductase inhibitor 3 month presume 2 time higher actual PSA level ) Has take unstable dose 5αreductase inhibitor like finasteride dutasteride past 3 month expect change dosage trial .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>strong</keyword>
	<keyword>silodosin</keyword>
	<keyword>benign prostatic hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>low urinary tract symptom associate severe BPH</keyword>
</DOC>